Your browser doesn't support javascript.
loading
Increased infections, but not viral burden, with a new SARS-CoV-2 variant
Ann Sarah Walker; Karina Doris Vihta; Owen Gethings; Emma Pritchard; Joel Jones; Thomas House; Iain Bell; John Bell; John Newton; Jeremy Farrar; Ian Diamond; Ruth Studley; Emma Rourke; Jodie Hay; Susan Hopkins; Derrick W Crook; Tim Peto; Philippa Matthews; David W Eyre; Nicole W Stoesser; Koen Pouwels; - the COVID-19 Infection Survey team.
Afiliação
  • Ann Sarah Walker; University of Oxford
  • Karina Doris Vihta; University of Oxford
  • Owen Gethings; Office for National Statistics
  • Emma Pritchard; University of Oxford
  • Joel Jones; Office for National Statistics
  • Thomas House; University of Manchester
  • Iain Bell; Office for National Statistics
  • John Bell; University of Oxford
  • John Newton; Public Health England
  • Jeremy Farrar; Wellcome Trust
  • Ian Diamond; Office for National Statistics
  • Ruth Studley; Office for National Statistics
  • Emma Rourke; Office for National Statistics
  • Jodie Hay; University of Glasgow
  • Susan Hopkins; Public Health England
  • Derrick W Crook; NIHR Oxford Biomedical Research Centre
  • Tim Peto; University of Oxford
  • Philippa Matthews; University of Oxford
  • David W Eyre; University of Oxford
  • Nicole W Stoesser; University of Oxford
  • Koen Pouwels; University of Oxford
  • - the COVID-19 Infection Survey team;
Preprint em En | PREPRINT-MEDRXIV | ID: ppmedrxiv-21249721
ABSTRACT
BackgroundA new variant of SARS-CoV-2, B.1.1.7/VOC202012/01, was identified in the UK in December-2020. Direct estimates of its potential to enhance transmission are limited. MethodsNose and throat swabs from 28-September-2020 to 2-January-2021 in the UKs nationally representative surveillance study were tested by RT-PCR for three genes (N, S and ORF1ab). Those positive only on ORF1ab+N, S-gene target failures (SGTF), are compatible with B.1.1.7/VOC202012/01. We investigated cycle threshold (Ct) values (a proxy for viral load), percentage of positives, population positivity and growth rates in SGTF vs non-SGTF positives. Results15,166(0.98%) of 1,553,687 swabs were PCR-positive, 8,545(56%) with three genes detected and 3,531(23%) SGTF. SGTF comprised an increasing, and triple-gene positives a decreasing, percentage of infections from late-November in most UK regions/countries, e.g. from 15% to 38% to 81% over 1.5 months in London. SGTF Ct values correspondingly declined substantially to similar levels to triple-gene positives. Population-level SGTF positivity remained low (<0.25%) in all regions/countries until late-November, when marked increases with and without self-reported symptoms occurred in southern England (to 1.5-3%), despite stable rates of non-SGTF cases. SGTF positivity rates increased on average 6% more rapidly than rates of non-SGTF positives (95% CI 4-9%) supporting addition rather than replacement with B.1.1.7/VOC202012/01. Excess growth rates for SGTF vs non-SGTF positives were similar in those up to high school age (5% (1-8%)) and older individuals (6% (4-9%)). ConclusionsDirect population-representative estimates show that the B.1.1.7/VOC202012/01 SARS-CoV-2 variant leads to higher infection rates, but does not seem particularly adapted to any age group.
Licença
cc_by_nc_nd
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo: 1 Coleções: 09-preprints Base de dados: PREPRINT-MEDRXIV Idioma: En Ano de publicação: 2021 Tipo de documento: Preprint